Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate
Cancer Reports · 2025
DOI: 10.1002/cnr2.70369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Lena Huber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, University Medical Center Mannheim, Heidelberg University, Germany. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Head and neck squamous cell carcinoma (HNSCC) is a globally significant disease with poor survival outcomes. Immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have improved treatment paradigms, yet their real‐world efficacy and the factors influencing treatment outcomes remain underexplored.
Aims
This study aimed to evaluate real‐world outcomes of pembrolizumab and nivolumab therapy in patients with HNSCC and to identify clinical and laboratory factors associated with overall survival (OS), progression‐free survival (PFS), and objective response rate (ORR). Methods and Results We conducted a retrospective analysis of 45 HNSCC patients treated with pembrolizumab or nivolumab at the University Medical Center Mannheim. Patient‐specific factors, including tumor characteristics, PD‐L1 expression, and laboratory parameters, were assessed using Kaplan–Meier estimation, log‐rank tests, and multivariate regression models. The median OS and PFS were 10.4 months and 7.4 months, respectively, with an ORR of 22%. A tumor proportion score (TPS) ≥ 50% and absence of smoking or alcohol abuse significantly improved ORR, while female sex, high neutrophil‐to‐lymphocyte ratio (NLR), and elevated leukocyte counts were associated with inferior OS and PFS. Real‐world outcomes largely aligned with the pivotal trials Keynote‐048 and CheckMate 141.
Conclusion
This study underscores the predictive value of TPS and patient lifestyle factors in ICI treatment for HNSCC. The findings also highlight sex‐specific differences, as well as NLR and leukocyte count as potential prognostic factors. Larger, more diverse cohorts are needed to confirm these results and refine patient selection strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Head and Neck Surgery, University Medical Center Mannheim, Heidelberg University, Germany.
- Medical Faculty, Mainz University, Germany.
ORCID-Profile: Lena Huber, Anne Lammert, Claudia Scherl, Sonja Ludwig, Annette Affolter, Nicole Rotter, Frederic Jungbauer
Zitieren
APA
Huber, L., Kohler, C., Lammert, A., Scherl, C., Ludwig, S., Affolter, A., Rotter, N., & Jungbauer, F. (2025). Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate. Cancer Reports. https://doi.org/10.1002/cnr2.70369
Vancouver
Huber L, Kohler C, Lammert A, Scherl C, Ludwig S, Affolter A, et al. Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate. Cancer Reports. 2025. doi:10.1002/cnr2.70369
BibTeX
@article{Huber2025,
author = {Huber, Lena and Kohler, Constanze and Lammert, Anne and Scherl, Claudia and Ludwig, Sonja and Affolter, Annette and Rotter, Nicole and Jungbauer, Frederic},
title = {Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70369}
}
EUVIMED